STAT

Bedside drug production will truly enable personalized medicine

Bedside development of biopharmaceuticals, which bypasses the pharmaceutical industry, makes personalized medicine scientifically and economically possible.
Source: APStock

Making medicines tailored to the needs and characteristics of individual patients is the dream for many scientists. This kind of personalized medicine approach would provide treatment with the highest possible effectiveness and safety, and would also save money. But it requires rethinking how we make medications.

The starting point of personalized medicine can be traced to the completion of the Human Genome Project, which sequenced almost the entire human genome, in 2001. Since then, however, only a limited number of personalized pharmaceutical treatments have reached patients. Technical issues like the lack of validated genetic tests and biomarkers to predict

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Moderna Covid-flu Vaccine, A Paused Pfizer Study, And More
Moderna announced its combination Covid and flu vaccine generated stronger immune responses in older adults in a Phase 3 trial than individual vaccines.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Novo’s Wegovy Approval In China, A Merck KGaA Cancer Trial Failure, And More
Novo Nordisk's weight loss drug Wegovy has been approved in China, the country estimated to have the highest number of overweight or obese people.
STAT1 min readIntelligence (AI) & Semantics
STAT+: Q&A: Defining Responsible AI In Health Care, With CHAI CEO Brian Anderson
CHAI CEO Anderson wants to build public trust in AI and empower patients and providers to have more informed conversations.

Related